Patient no. | Sex | Age (years) | Eye | BCVA | Anterior segment features | Posterior segment features | Systemic features and steroid exposure | Total follow-up (weeks) |
---|---|---|---|---|---|---|---|---|
1 | M | 32 | OD | 0.8 | – | SSRD and PED | Nil | 6 |
OS | 0.2 | – | ||||||
2 | M | 41 | OD | 0 | – | – | Nil | 12 |
OS | 0.2 | SSRD | ||||||
3 | M | 33 | OD | 0.2 | – | – | Local steroid use for dermatological condition | 8 |
OS | 0.8 | SSRD | ||||||
4 | F | 38 | OD | 0 | – | – | Oral herbal medications for hypertension | 2 |
OS | 0.2 | SSRD and PED | ||||||
5 | M | 37 | OD | 0.8 | – | SSRD | Oral herbal medications for renal calculi | 8 |
OS | 0 | – | ||||||
6 | M | 32 | OD | 0.2 | – | – | Local steroid use for tinea | 4 |
OS | 0.48 | SSRD | ||||||
7 | M | 35 | OD | 0 | – | SSRD and PED | Oral steroids for asthma | 6 |
OS | 0 | – | ||||||
8 | M | 32 | OD | 0 | – | PED | Nil | 12 |
OS | 0.48 | SSRD and PED | ||||||
9 | M | 27 | OD | 0 | – | – | Nil | 14 |
OS | 0.3 | SSRD and PED | ||||||
10 | M | 32 | OD | 0.2 | – | SSRD | Nil | 9 |
OS | 0 | – | ||||||
11 | F | 24 | OD | 0.1 | – | SSRD and PED | Local steroid use for dermatological condition | 5 |
OS | 0.1 | – | ||||||
12 | M | 44 | OD | 0.3 | – | SSRD | Oral steroids for joint pains | 10 |
OS | 0 | – | ||||||
13 | M | 38 | OD | 0 | – | – | Nil | 12 |
OS | 0.1 | SSRD and PED | ||||||
14 | M | 39 | OD | 0.2 | – | SSRD and PED | Oral herbal medications for fatigue | 4 |
OS | 0 | – |